Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

The outcome of short-term low-dose aspirin treatment in Kawasaki disease based on inflammatory markers

  • Yoo, Jae Won (Department of Pediatrics, Chungnam National University School of Medicine) ;
  • Kim, Ji Mok (Department of Pediatrics, Chungnam National University School of Medicine) ;
  • Kil, Hong Ryang (Department of Pediatrics, Chungnam National University School of Medicine)
  • 투고 : 2016.09.08
  • 심사 : 2016.10.21
  • 발행 : 2017.01.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Previously, Kawasaki disease (KD) treatment with low-dose aspirin was administered for 6-8 weeks after the acute phase. However, inflammatory marker levels normalize before 6-8 weeks. In this study, we aimed to investigate the clinical outcome of short-term low-dose aspirin treatment based on inflammatory and thrombotic marker levels. Methods: We performed a retrospective review of the medical records of patients with KD who were hospitalized at Chungnam National University Hospital between September 2012 and May 2014. When fever subsided, low-dose aspirin treatment was started. Inflammatory (white blood cell count, erythrocyte sedimentation rate, and C-reactive protein) and thrombotic markers (D-dimer) were monitored at follow-ups conducted in 1- to 2-week intervals. The low-dose aspirin administration was terminated when both markers were normalized and no cardiovascular complications were observed. Results: Eighty-four patients with KD (complete KD, n=49; incomplete KD, n=35) were enrolled. The inflammatory and thrombotic marker levels were normalized within 3-4 weeks on average. At the beginning the low-dose aspirin treatment, 9 patients had coronary artery lesions but 75 did not. When the low-dose aspirin administration was terminated at the time the inflammatory marker levels were normalized, no new CALs developed during the follow-up at 6-8 weeks. Conclusion: Most of the inflammatory marker levels were normalized within 3-4 weeks after the acute phase of KD. New cardiovascular complications did not develop during the course of the short-term aspirin treatment based on the inflammatory marker levels, clinical findings, and echocardiography.

키워드

참고문헌

  1. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. https://doi.org/10.1542/peds.2004-2182
  2. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J 2014;78:2521-62. https://doi.org/10.1253/circj.CJ-66-0096
  3. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr Infect Dis J 2014;33: 24-7. https://doi.org/10.1097/INF.0000000000000010
  4. Kang HJ, Kim GN, Kil HR. Changes of clinical characteristics and outcomes in patients with Kawasaki disease over the past 7 years in a single center study. Korean J Pediatr 2013;56:389-95. https://doi.org/10.3345/kjp.2013.56.9.389
  5. Akagi T, Kato H, Inoue O, Sato N. Salicylate treatment in Kawasaki disease: high dose or low dose? Eur J Pediatr 1991;150:642-6. https://doi.org/10.1007/BF02072625
  6. Williams RV, Tcheng WY, Minich LL. Anticoagulation in the acute and long-term management of Kawasaki disease. Prog Pediatr Cardiol 2004:19:179-88. https://doi.org/10.1016/j.ppedcard.2004.08.012
  7. Israels SJ, Michelson AD. Antiplatelet therapy in children. Thromb Res 2006;118:75-83. https://doi.org/10.1016/j.thromres.2004.12.016
  8. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10. https://doi.org/10.1111/j.1442-200X.1991.tb02612.x
  9. Yamakawa R, Ishii M, Sugimura T, Akagi T, Eto G, Iemura M, et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998;31:1074-80. https://doi.org/10.1016/S0735-1097(98)00033-3
  10. Dhillon R, Clarkson P, Donald AE, Powe AJ, Nash M, Novelli V, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996;94:2103-6. https://doi.org/10.1161/01.CIR.94.9.2103
  11. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17. https://doi.org/10.1016/S0140-6736(06)68040-9
  12. Oh IJ, Moon KH, Hong ME, Kim YS, Lee CW, Yoon HS. Clinical significance of follow-up laboratory tests, performed at 6 weeks after the onset of Kawasaki disease. Korean J Pediatr 2006;49:672-6. https://doi.org/10.3345/kjp.2006.49.6.672
  13. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78. https://doi.org/10.1542/peds.105.6.e78
  14. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80. https://doi.org/10.1067/mpd.2000.107890
  15. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
  16. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma -globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
  17. Kobayashi T, Inoue Y, Tamura K, Morikawa A, Kobayashi T. External validation of a scoring system to predict resistance to intravenous immunoglobulin. J Pediatr 2007;150:e37. https://doi.org/10.1016/j.jpeds.2006.12.036
  18. Scott JS, Ettedgui JA, Neches WH. Cost-effective use of echocardiography in children with Kawasaki disease. Pediatrics 1999;104:e57. https://doi.org/10.1542/peds.104.5.e57
  19. McMorrow Tuohy AM, Tani LY, Cetta F, Lewin MB, Eidem BW, Van Buren P, et al. How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease? Am J Cardiol 2001;88:328-30. https://doi.org/10.1016/S0002-9149(01)01655-1